Matt Callahan is a Perth-raised life sciences and health tech executive currently based in Pennsylvania. He had spent more than 25 years in legal, IP and investment management roles.
Mr Callahan has been the founding chief executive or executive director of several pharmaceutical and health tech companies including ASX-listed Botanix Pharmaceutical, iCeutica, Churchill Pharma, Dimerix Biosciences, Emerald Clinics, Orthocell, and Respirion Pharmaceutical. He has led the development of four products that have received FDA approval.
Mr Callahan has worked as an investment director for two venture capital firms investing in life sciences, technology and other sectors; and was general manager of Australian listed technology and licensing company ipernica (now Nearmap ASX:NEA), where he was responsible for the licensing programs that generated more than $120M in revenue.
Mr Callahan holds a Bachelor of Laws (Honours) from the University of WA, an MBA, and is a winner of the Business News 40under40 award in 2002.
